Business Context and Reporting Period
This Form 8-K was filed by XpresSpa Group, Inc. (trading symbol: XSPA) on August 25, 2020, reporting a material definitive agreement entered into on the same date. The filing details a registered direct offering of common stock and warrants, with the transaction closing on August 28, 2020.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $35.3 million raised from the offering.
- Offering Price: $3.15 per share (combined price for shares and warrants).
- Securities Issued:
- 10,407,408 shares of Common Stock.
- Warrants exercisable for 11,216,932 shares of Common Stock.
- 809,524 Pre-Funded Warrants (exercisable for one share each).
- Warrant Terms: Exercise price of $3.02 per share; immediately exercisable; expire 24 months from issuance.
- Pre-Funded Warrant Terms: Purchase price of $3.149 per unit; exercise price of $0.001 per share.
- Placement Agent Fees: 7.5% cash fee plus 1.0% management fee on gross proceeds, plus reimbursement of expenses and legal fees up to $40,000.
- Placement Agent Warrants: Warrants to purchase up to 897,355 shares issued to the placement agent (H.C. Wainwright & Co., LLC) with an exercise price of $3.9375 per share.
Material Changes and Ownership Limits
The filing discloses a significant capital raise intended to provide liquidity. A material change involves the issuance of new equity and warrants, which will increase the total number of outstanding shares upon exercise. The agreement includes ownership limitations (blockers) preventing any holder from exercising warrants to own more than 4.99% of outstanding Common Stock immediately after exercise, unless the holder provides 61 days' prior notice to increase the limit to 9.99%.
Outlook, Risks, and Management Commentary
The filing does not provide specific forward-looking financial guidance, revenue projections, or management commentary regarding future operational performance. The primary focus is the execution of the financing transaction. Risks associated with the transaction include potential dilution to existing shareholders upon the exercise of warrants and pre-funded warrants. The placement agent has secured a right of first refusal to act as financial advisor or underwriter for future debt and equity transactions for a period of twelve months following the closing.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-closing to calculate the dilution impact of the 11.2 million warrants and 809,524 pre-funded warrants.
- Confirm the net proceeds after deducting the 8.5% total placement agent fees and other offering expenses.
- Review the attached Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions on the use of proceeds.
- Monitor the exercise price of $3.02 relative to the current market price to assess the likelihood of warrant exercise.
- Check for any subsequent filings regarding the utilization of the $35.3 million in gross proceeds.